14-day Premium Trial Subscription Sign Up For FreeGet Free

Citius Pharmaceuticals Inc Stock Forecast NASDAQ:CTXR

$1.85 (0.54%)

Volume: 2M

Closed: Dec 08, 2021

Hollow Logo Score: 1.696

Citius Pharmaceuticals Inc Stock Forecast

$1.85 (0.54%)

Volume: 2M

Closed: Dec 08, 2021

Score Hollow Logo 1.696
Which way will CTXR go? Request
Stop-loss: $1.79 (-3.40%)
Earnings Date: Dec 15, 2021
Key Stats
Beta 1.08
* StockInvest.us uses dynamically calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behavior.
RSImin/max Values: [ 25 - 75 ] RSI14 is 55 and the stock is currently not being overbought or oversold

Citius Pharmaceuticals Inc stock price up 0.54% on Wednesday
(Updated on Dec 08, 2021)


Buy candidate since 2021-12-07 Gain 0.54%

The Citius Pharmaceuticals Inc stock price gained 0.54% on the last trading day (Wednesday, 8th Dec 2021), rising from $1.84 to $1.85. , and has now gained 4 days in a row. It will be exciting to see whether it manages to continue gaining or take a minor break for the next few days. During the day the stock fluctuated 8.14% from a day low at $1.72 to a day high of $1.86. The price has been going up and down for this period, and there has been a 10.12% gain for the last 2 weeks. Volume fell on the last day by -1 million shares and in total, 2 million shares were bought and sold for approximately $3.64 million. You should take into consideration that falling volume on higher prices causes divergence and may be an early warning about possible changes over the next couple of days.

The stock lies the upper part of a very wide and falling trend in the short term, and this may normally pose a very good selling opportunity for the short-term trader as reaction back towards the lower part of the trend can be expected. A break up at the top trend line at $1.91 will firstly indicate a slower falling rate, but may be the first sign of a trend shift. Given the current short-term trend, the stock is expected to fall -20.07% during the next 3 months and, with a 90% probability hold a price between $1.19 and $1.53 at the end of this 3-month period. Do note, that if the stock price manages to stay at current levels or higher, our prediction target will start to change positively over the next few days as the conditions for the current predictions will be broken.

Signals & Forecast

Mostly positive signals in the chart today. The Citius Pharmaceuticals Inc stock holds buy signals from both short and long-term moving averages giving a positive forecast for the stock, but the stock has a general sell signal from the relation between the two signals where the long-term average is above the short-term average. On corrections down, there will be some support from the lines at $1.67 and $1.81. A breakdown below any of these levels will issue sell signals. A buy signal was issued from a pivot bottom point on Friday, December 03, 2021, and so far it has risen 22.52%. Further rise is indicated until a new top pivot has been found. Furthermore, there is a buy signal from the 3 month Moving Average Convergence Divergence (MACD). Volume fell during the last trading day despite gaining prices. This causes a divergence between volume and price and it may be an early warning. The stock should be watched closely.

Support, Risk & Stop-loss

Citius Pharmaceuticals Inc finds support from accumulated volume at $1.84 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.

This stock has average movements during the day and with good trading volume, the risk is considered to be medium. During the last day, the stock moved $0.14 between high and low, or 8.14%. For the last week, the stock has had a daily average volatility of 8.08%.

Our recommended stop-loss: $1.79 (-3.40%) (This stock has medium daily movements and this gives medium risk. There is a buy signal from a pivot bottom found 3 days ago.)

Is Citius Pharmaceuticals Inc stock A Buy?

Several short-term signals are positive, despite the stock being in a falling trend, we conclude that the current level may hold a buying opportunity as there is a fair chance for stock to perform well in the short-term.

Current score: 1.696

Predicted Opening Price for Citius Pharmaceuticals Inc of Thursday, December 9, 2021

The predicted opening price is based on yesterday's movements between high, low, and the closing price.

Fair opening price December 9, 2021 Current price
$1.81 $1.85 (Overvalued)
Buy Candidate Unchanged

Remember To Visit Our YouTube Channel

Analyst Ratings

On Nov 30, 2021 "Maxim Group" gave "$4.00" rating for CTXR. The price target was set to $1.64+1.2%.

Volatility and Risk
Daily Average Volatility: 8.08 %
Overall Risk: Very High High Medium Low Very Low
Volatility
8.08 %
Daily Average Volatility
Overall Risk

Very High
High
Medium
Low
Very Low

Support & Resistance

Resistance: $1.98
Price: $1.85
Support: $1.84

CTXR Insider Trading Show all Trades

INSIDER POWER

Last 87 transactions
Buy: 50 786 000 | Sell: 0 (Shares)
Date Action Amount Person Type
Oct 11, 2021 Buy 75 000 Safir Howard Options to Purchase Common Stock
Oct 11, 2021 Buy 300 000 Czuczman Myron Stock Option (Right to Purchase Common Stock)
Oct 11, 2021 Buy 75 000 Kane William Options to Purchase Common Stock
Oct 11, 2021 Buy 15 000 Holubiak Myron Z Options to Purchase Common Stock
Oct 11, 2021 Buy 650 000 Holubiak Myron Z Options to Purchase Common Stock
Show all Insider Trades
INSIDER POWER

Last 87 transactions
Buy: 50 786 000 | Sell: 0 (Shares)

Fibonacci Support & Resistance Levels

Level Price Change
Resistance 1.95 5.41 %
1.90 2.51 %
1.86 0.73 %
Current price: 1.85
Support 1.76 -5.05 %
1.72 -6.84 %
1.67 -9.73 %

Accumulated Volume Support & Resistance Levels

Level Price Chg %
Resistance 2.09 12.97 %
2.03 9.73 %
1.98 7.03 %
Current price 1.85
Support 1.84 -0.54%
1.81 -2.16%
1.69 -8.65%

Click to get the best stock tips daily for free!

About Citius Pharmaceuticals Inc

Citius Pharmaceuticals Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes therapeutic products in the United States. The company offers Suprenza ODT, a phentermine orally disintegrating tablet that is used for the treatment of obesity. Its products also include Hydrocortisone-Lidocaine Cream, which is under phase II of clinical trial for the treatment of hemorrhoids. The company has a collaboration and license agreement with A... Read more

Golden Star Signal

This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.

This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!

Get access to Golden Star list now!

StockInvest.usJoin 100 000+ Happy Subscribers

Don't miss out on the runners!

Get The StockInvest.Us Newsletter

StockInvest.usStock Podcast

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT